- Home
- ILLR vs EXAI Comparison
ILLR vs EXAI Comparison
Compare ILLR & EXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- EXAI
- Stock Information
- Founded
- ILLR 2015
- EXAI 2012
- Country
- ILLR United States
- EXAI United Kingdom
- Employees
- ILLR N/A
- EXAI N/A
- Industry
- ILLR Investment Managers
- EXAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ILLR Finance
- EXAI Health Care
- Exchange
- ILLR Nasdaq
- EXAI Nasdaq
- Market Cap
- ILLR 663.4M
- EXAI 635.8M
- IPO Year
- ILLR N/A
- EXAI 2021
- Fundamental
- Price
- ILLR $4.13
- EXAI $5.28
- Analyst Decision
- ILLR
- EXAI Hold
- Analyst Count
- ILLR 0
- EXAI 4
- Target Price
- ILLR N/A
- EXAI $7.00
- AVG Volume (30 Days)
- ILLR 1.3M
- EXAI 485.2K
- Earning Date
- ILLR 11-21-2024
- EXAI 11-15-2024
- Dividend Yield
- ILLR N/A
- EXAI N/A
- EPS Growth
- ILLR N/A
- EXAI N/A
- EPS
- ILLR N/A
- EXAI N/A
- Revenue
- ILLR $46,338,000.00
- EXAI $26,566,153.00
- Revenue This Year
- ILLR N/A
- EXAI $156.33
- Revenue Next Year
- ILLR N/A
- EXAI N/A
- P/E Ratio
- ILLR N/A
- EXAI N/A
- Revenue Growth
- ILLR N/A
- EXAI N/A
- 52 Week Low
- ILLR $0.66
- EXAI $3.80
- 52 Week High
- ILLR $8.86
- EXAI $7.91
- Technical
- Relative Strength Index (RSI)
- ILLR N/A
- EXAI 57.06
- Support Level
- ILLR N/A
- EXAI $4.80
- Resistance Level
- ILLR N/A
- EXAI $5.26
- Average True Range (ATR)
- ILLR 0.00
- EXAI 0.23
- MACD
- ILLR 0.00
- EXAI 0.03
- Stochastic Oscillator
- ILLR 0.00
- EXAI 81.16
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About EXAI Exscientia Plc
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.